Opinion: leading position of ultrasound in decision algorithm for small papillary thyroid carcinoma

Pierre Yves Marcy1*, Gilles Russ2, Luca Saba3, Julie Sanglier4, Edouard Ghanassia5, Haithem Sharara6, Juliette Thariat7, Jean Baptiste Morvan8 and Alain Bizeau9

Keywords: Watchful waiting, Radiofrequency ablation, Papillary thyroid cancer, Ultrasonography, Thyroid

Key points

- Doppler US has a leading position in selecting patients with low-risk PTC.
- Multiparametric ultrasound assessment and appropriate settings are mandatory.
- Five PTC characteristics should be labelled and reported on standard scheme.
- Unfavourable factors, RLN palsy, suspicious US/FNA rule out active surveillance.
- Percutaneous RFA can be an option for patients eligible for active surveillance.

This Opinion article reports our view regarding the course of action to be taken when facing T1 papillary thyroid carcinoma, and the leading role of ultrasound in the decision algorithm.

This is an opinion letter and a reply letter to the article “Ultrasound in active surveillance for low-risk papillary thyroid cancer: imaging considerations in case selection and disease surveillance” recently published, we congratulate the authors Ghai et al. and would like to make further comments.

The baseline thyroid scans evaluated up to 4 nodules at study outset. PTC’s size in 3 dimensions, precise location of the nodule (along the course of recurrent laryngeal nerve abutting the trachea, upper, mid, lower third, isthmus, sub capsular, extrathyroidal extension) or evidence of nodal metastases were recorded. All patients had 6-month interval scan follow-up for the first 2 years and then yearly.

We agree with the authors for storing a key-image displaying the malignant thyroid nodule on PACS; we strongly advocate to report, on an additional standardised identification scheme (Fig. 1), the precise characteristics of the malignant nodule (pT1a vs pT1b, presence of multiple similar tumour foci, location, presence of hyperechoic foci suggestive of microcalcifications, extra thyroid extension ETE), the allocated Eu-TIRADS score, location of suspicious lymph node (s) according to the Robbins’s classification [2], and TNM classification. The distribution of microcalcifications in the thyroid gland should also be assessed. Widespread microcalcifications, especially when associated with suspicious cervical lymph nodes in a young patient < 20 years old are suspect of a diffuse sclerosing variant of PTC.

As reported by Ghai et al., we also note the presence of thyroiditis (reduction of thyroid gland echogenicity, reactive adenitis at level VI, positive serum anti-Thyroid peroxidase (ATPO) antibody level) when available, and label other non-suspicious nodules (Fig. 1). In lymphocytic
thyroiditis and/or Grave’s disease settings, we agree with Ghai et al. regarding the difficulty of diagnosis and follow up of malignant hypoechoic nodules that may limit accurate reproducible measurements of thyroid nodules. Doppler US and microvascular imaging as well as elastography optimise delineation and accurate measurement in three dimensions of the target tumour [3]. To better characterise isoechoic suspicious nodules, one should decrease the dynamic range settings to increase the contrast ratio between the target nodule and the contiguous thyroid gland.

As auto-immune processes frequently render thyroid gland hypoechoic, the contrast with a hypoechoic nodule can be reduced or suppressed. Sometimes, the use of elastography can show a zone of focal increased stiffness corresponding to the nodule, therefore helping to detect and assert its existence. If strain elastography [4, 5] is applied, the use of a nodule-to-muscle ratio could be more helpful than a nodule-to-surrounding thyroid parenchyma, due to the modifications of the latter in chronic autoimmune thyroiditis.

It is worthy to note that the authors applied the rule of nodule measurement follow-up that was dedicated to T1a thyroid microcarcinomas ($T < 10 \text{ mm}$) according to the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma [6], whereas the authors also included T1b tumours ($10 \text{ mm} < T < 20 \text{ mm}$) in their study [1]. Thus, any disease progression prompting surgical recommendation ($>3 \text{ mm}$ in anyone dimension according to ACR

---

**Fig. 1** Thyroid nodule labelling and numbering at study outset (and follow-up). A Axial US scan of upper right lobe of thyroid gland. B Sagittal scan of right lobe. C Axial scan of right lobe and isthmus. D Diagram. Nodules are numbered from upper to lower lobe from right to left. In case of multifocal malignant nodule, various tumour foci are identified on US scan (A–C) as N1*, N3*, N4* and N5*, and reported on the diagram (D). Sum of each focus is calculated: $7 \text{ mm (upper right lobe)} + 3 \text{ mm (lower right lobe)} + 3 \text{ mm (isthmus)} + 2 \text{ mm (isthmus)} = 15 \text{ mm (pT1b)}$ (D). Note that considering the only main tumour focus (N1) leads to pT1a diagnosis according to the TNM classification. Echogenic foci should be differentiated from comet tail artefacts and are considered as psammoma body microcalcifications and be reported.
TI-RADS nodule’s orientation) represents a 15% cut-off long axis progression in T1b compared to 30% in T1a thyroid carcinomas [1, 6]. Moreover, the choice of using a single diameter and not a volume increase is debatable. Rozenbaum et al. [7] found a volume progression ≥ 50% in 35.0% (at any time during the follow-up) and 26.3% of patients (if considering first and last follow-up), whereas a diameter increase of ≥ 3 mm was seen in 3.8% of cases only. Thus, we advise the use of volume as a supplementary criterion of nodule increase, with a cut-off of 50%.

To reduce interobserver variation, proceeding to multiple measurements of the same nodule usually allows to more accurate estimations. Noteworthy, we should keep in mind that thyroid US may overestimate by 2 mm the size of pT1a thyroid carcinomas [7], and by 19.5% the pT1b cystic like carcinomas size, when compared to the definitive gross histological size [8].

In case of macrocalcification, we use multiparametric ultrasonography assessment, shifting from lower to higher frequency ultrasonography (US) neck probe. Adjusting the bandwidth frequency of the US probe, focusing on suspicious area of interest (when not automatic) will help to better assess the nodule’s outlines and measure the target nodule.

The distribution of microcalcifications in the thyroid gland should also be assessed. Widespread microcalcifications, especially when associated with suspicious cervical lymph nodes in a young patient are suspect of a diffuse sclerosing variant of PTC (DSV). Dispersed echogenic foci of PTC islands, the so-called psammoma

---

**Fig. 2** US scan of two diffuse Sclerosing Variants (DSV) of PTC. Case 1 Longitudinal US scan of right lobe (A), histopathological specimen (B, 20 x). DSV shows diffuse extensive psammoma bodies (O) of thyroid lobe (A, B), usually without forming a gross tumour nodule. In the present case, a dominant 9 mm Eu-TIRADS4 anterior nodule T1a is displayed (A, ++). Case 2 Longitudinal US scan shows Eu-TIRADS5 posterior thyroid nodule (C). Doppler US discloses twinkling artefacts of psammoma microcalcifications on Doppler US (D). TNM staging: the radiologist takes into account the PTC nodule size, whereas the histopathologist takes into account the nodule size but also the long axis of microcalcifications, which correspond to intra lymphatic intralobar thyroid tumour spread.
bodies, metastasise into dilated lymphatics vessels (Fig. 2) and may represent a formal contraindication to active surveillance [9].

According to TNM eighth edition [10], gross extra-thyroidal extension invading strap muscles is considered as stage T3b, while invasion into soft tissues, larynx, trachea, oesophagus, recurrent laryngeal nerve (RLN) is staged T4a, whatever the tumour size.

Regarding extra-thyroidal extension, the authors excluded from the active surveillance the PTC presenting with ETE criteria. The latter include (a) abutment; (b) disruption, loss of perithyroid echogenic line at site of contact with the known cancerous nodule; (c) contour bulging, and (d) replacement of strap muscle, with indistinct margin with the strap muscle (for gross ETE). Interestingly, we noticed that Doppler US and novel microvascular imaging technique can be of significant value to predict ETE, namely when tiny vessels are shown running along or perpendicular to the thyroid nodule capsule [11]. Adjusting the field of view, the probe frequency bandwidth and the focus zone will increase thyroid capsular vessel flow imaging and subsequent prediction of ETE (Fig. 3). However, in posterior and deep located thyroid nodule, microvascular imaging (MVI) seems of limited value, and computed tomography (CT) should be considered as a further diagnosis step of ETE to the oesotracheal groove, as recommended by Ghai et al. [1].

Upper lobe location has been linked to a higher risk of lateral lymph node, skip metastasis [12], and lymph node recurrence, and should be considered at the initial description and be reported on the study outset scheme for further assessment of PTC (Fig. 1). According to Seok et al., PTC location at the isthmus comprises 4.6%
of all PTCs and have more lymphatic invasion (22.1% vs. 13.4%), ETE (73.0% vs. 57.1%), and perithyroidal and prelaryngeal node metastasis (18.0% vs. 9.0%) compared to lobar PTCs [13]. Thus, active surveillance should be considered on a case-by-case basis, namely in patients presenting with less than 10 mm thickness isthmus PTC.

Microvascular imaging tools such as Super Microvascular Imaging® (SMI) could be more sensitive and specific than conventional US Doppler for the detection of suspicious lymph nodes. This is due to the improvement in detecting very low vascular flows and in the imaging resolution [14].

Interestingly, level I is never involved in case of lymphatic metastatic thyroid spread. US has a low diagnostic sensitivity (around 50% or less) in case of level VI involvement. However particular attention should be paid to lower neck level VI nodes as further lymphatic tumour spread could lead to upper mediastinal lymphadenopathy that will require further thoracic surgery in aggressive tumours. Risk factors for upper mediastinum lymph node metastasis include strong lymphatic involvement of level VI (> 50%) and level IV (> 33%), increased serum Thyroglobulin (Tg) and anti-Tg antibodies level [15].

Interestingly, percutaneous radiofrequency Ablation (RFA) might represent another safe effective alternative for managing low-risk small PTCs, especially in patients ineligible for surgery. RFA has been advocated as so by the European Thyroid Association and CIRSE guidelines [16] (Fig. 4). A meta-analysis, analysing results of RFA in 1284 PTCs demonstrated that complete disappearance was 76.2% and recurrence rate 0.01% after RFA [17].

Thus, a decision algorithm could help the referring physician (Fig. 5). One should consider the existence of a family history [18] of thyroid cancer (5.9%), other unfavourable or aggressive factors leading to surgery, such
as cytological/molecular aggressive features [9, 19] the life expectancy and advice of the patient. Finally, even though the vast majority of PTC has an indolent course, some can be revealed by a neck node [20] or exceptionally develop a fulminant lethal course [21]. In all other cases, RFA could be proposed as an alternative to active surveillance and surgery.

**Abbreviations**

ACR TI-RADS: American College of Radiology-Thyroid Imaging Reporting and Data System; ATPO: AntiThyroPerOxidase antibodies; DSV: Diffuse sclerosing variant; ETE: Extrathyroidal extension; Eu-TIRADS: European thyroid imaging reporting and data system; FNA: Fine needle aspiration; MVA: Microvascular imaging; PTC: Papillary thyroid cancer; RFA: Radiofrequency ablation; RLN: Recurrent laryngeal nerve; Tg: Thyroglobulin; US: Ultrasound.

**Acknowledgements**

On behalf of the AFTHY, Association Francophone de THYroïdologie, we thank Professor JH BAEK for providing Fig. 4 and his always thoughtful remarks.

**Author contributions**

All authors have read and approved the Opinion article.

**Funding**

This Opinion article has not received any funding.

**Availability of data and materials**

All data and material are included in this Opinion article.

**Declarations**

**Ethics approval and consent to participate**

All presentations of US and histopathological samples have obtained consent to be published.

**Consent for publication**

All authors consent to the publication.

**Competing interests**

The authors declare no competing interests.

**Author details**

1Department of Radiodiagnosics and Interventional Imaging, Polyclinics ELSAN Group, PolyClinics Les Fleurs, Quartier Quiez, 83189 Ollioules, France.
2Centre de Pathologie et d’Imagerie Paris 14ème, Unité Thyroïde et Tumeurs Endocrines, Hôpital La Pitié Salpetrière, 83 Bd de l’Hôpital, Sorbonne Université, Paris, France.
3Department of Radiology, Humanitas Mater Domini, Castellanza, VA, Italy.
4Department of Ultrasound, Antoine Lacassagne Cancer Centre, Nice, France.

**Fig. 5** Decision algorithm regarding PTC. Thyroid US is central in decision algorithm of small size PTC. Unfavorable factors, including young age < 20 years, previous radiation exposure and family history of thyroid cancer [18], and recurrent laryngeal nerve (RLN) palsy should lead to thyroid surgery. Five US criteria, including size > 7 mm, particular location, ETE, DSV features, suspicious lymph nodes, associated with aggressive behaviour (cytology, molecular) on FNA should lead to surgery [9, 19]
Research Institute, Sophia Antipolis University, 33 Avenue Valombreuse, Nice Cedex, France. 5 American Hospital of Paris, 63 bd Victor Hugo, Neuilly sur Seine, France. 6 Department of Radiology, University Hospital, Place du Pr R. Debré, Nîmes Cedex 9, France. 7 Department of Radiation Oncology, Cancer Research Institute Francois Baclesse, 3 Avenue Général Harris, Caen, France. 8 Department of Head and Neck Surgery, University Military Hospital Sainte-Anne, 2, Boulevard Sainte Anne, BP 600, Toulon, France. 9 Department of Head and Neck Surgery, Sainte Musse Hospital, 54, Rue Henri Sainte Claire Deville, Toulon, France.

Received: 22 March 2022   Accepted: 22 May 2022

Published online: 07 June 2022

References

1. Ghai S, O’Brien C, Goldstein DP, Sawka AM, Canadian Thyroid Cancer

2. Robbins KT (1998) Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin N Am 31(4):639–655. https://doi.org/10.1016/s0030-6665(05)70077-3

3. Liu B, Liang J, Zheng Y et al (2015) Two-dimensional shear wave elastography as promising diagnostic tool for predicting malignant thyroid nodules: a prospective single-centre experience. Eur Radiol 25(3):624–634. https://doi.org/10.1007/s00330-014-3455-8

4. Cepēna CM, Paul C, Borlea A et al (2020) The value of strain elastography in predicting autoimmune thyroiditis. Diagnostics (Basel) 10(11):874. https://doi.org/10.3390/diagnostics10110874

5. Görgülü FF (2019) Which is the best reference tissue for strain elastography? J Ultrasound Med 38(11):3053–3064. https://doi.org/10.1002/jum.15013

6. Sugitani I, Ito Y, Takeuchi D et al (2021) Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. Thyroid 31(2):183–192. https://doi.org/10.1089/thy.2020.0330

7. Rozenbaum A, Buffet C, Bigrigne C et al (2021) Outcomes of active surveillance of EU-TIRADS 5 thyroid nodules. Eur J Endocrinol 184(5):677–686. https://doi.org/10.1530/EJE-20-1481

8. Lacout A, Chamorey E, Thariat J et al (2017) Insight into differentiated thyroid cancer gross pathological specimen shrinkage and its influence on TNM staging. Eur Thyroid J 6(6):315–320. https://doi.org/10.1159/000478774

9. Lloyd RV, Buehler D, Khanashfar E (2011) Papillary thyroid carcinoma variants: Head Neck Pathol 5(1):51–56. https://doi.org/10.1007/s12348-010-0236-9

10. Tuttle RM, Haugen B, Perrier ND (2017) Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27(6):751–756. https://doi.org/10.1089/thy.2017.0102

11. Lacout A, Chevenet C, Marcy PY (2015) Insights in local extrathyroidal invasion of papillary thyroid carcinoma on Doppler ultrasound examination. AJR Am J Roentgenol 204(3):372–373. https://doi.org/10.2214/AJR.14.13839

12. Liu Y, Xu SY, Liu K et al (2021) Prediction and investigation of the potential risk factors for the upper mediastinal metastasis of papillary thyroid carcinoma. Zhonghua Zhong Liu Za Zhi 43(4):477–483

13. Mauri G, Hagedus L, Bandula S et al (2021) European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J 10(3):185–197. https://doi.org/10.1159/000516469

14. Lee S, Lee JY, Yoon RG, Kim JH, Hong HS (2020) The value of microvascular imaging for triaging indeterminate cervical lymph nodes in patients with papillary thyroid carcinoma. Cancers (Basel) 12(10):2839. https://doi.org/10.3390/cancers12102839

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.